Enzyme test could open door to new dementia therapy

NCT ID NCT05304195

Completed Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study measured the activity of an enzyme called glucocerebrosidase in 236 people with and without Lewy body dementia. The goal was to see if lower enzyme activity could help identify patients who might benefit from treatments already used for Gaucher disease. The study did not test any treatment, but its results could guide future therapeutic trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If this study shows that glucocerebrosidase activity is lower in people with Lewy body dementia, it could point toward using existing Gaucher disease treatments for this condition.
What could go wrong: This is an observational study that only measures enzyme activity—it does not test any treatment. The results may not lead to a therapy, and any future trials would still need to prove safety and effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEMENTIA WITH LEWY BODIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Lewy body dementia Lewy Body Disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DEMENTIA WITH LEWY BODIES

Contacts and locations

Locations

Centre de neurologie Cognitive

Paris, France, 75010, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.